-+ 0.00%
-+ 0.00%
-+ 0.00%

Prime Medicine Presents Wilson Disease Gene-Editing Trial Plans, Targets Initial Data in 2027

PUBT·11/10/2026 22:07:22
Listen to the news
Prime Medicine Presents Wilson Disease Gene-Editing Trial Plans, Targets Initial Data in 2027
  • Prime Medicine expects initial clinical data in 2027 for PM577a in Wilson disease and PM647 in alpha-1 antitrypsin deficiency.
  • The PM577a clinical trial has begun; PM647 has received investigational new drug clearance.
  • A biologics license application for PM359 in chronic granulomatous disease is planned for 2027, subject to final FDA alignment.
  • Follow-on Wilson disease programs will reuse the liver-targeted delivery platform to address additional mutations.
  • Additional strategic partnerships are targeted to accelerate pipeline development and bolster financial resources.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.